1. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer
- Author
-
Stephen Dann, Howard A Burris rd, Erika Hamilton, Heike Krupka, Gilbert Y. Wong, Komal Jhaveri, Timothy A. Yap, Geoffrey I. Shapiro, Feng Liu, Jonathan W. Goldman, and Hope S. Rugo
- Subjects
0301 basic medicine ,Breast Neoplasms ,Cyclin-Dependent Kinase Inhibitors ,03 medical and health sciences ,0302 clinical medicine ,Cyclin-dependent kinase ,medicine ,Humans ,Pharmacology (medical) ,Protein Kinase Inhibitors ,Cellular transcription ,biology ,Transition (genetics) ,Kinase ,business.industry ,Cell Cycle ,Cancer ,Cyclin-Dependent Kinase 4 ,Cyclin-Dependent Kinase 6 ,Cell cycle ,medicine.disease ,Cyclin-Dependent Kinases ,Cell biology ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,biology.protein ,Female ,biological phenomena, cell phenomena, and immunity ,business - Abstract
Introduction: The cell cycle cyclin-dependent kinases (CDKs) play a critical role in controlling the transition between cell cycle phases, as well as cellular transcription. Aberrant CDK activation...
- Published
- 2021